Direkt zum Inhalt
Merck

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Bioorganic & medicinal chemistry letters (2005-06-01)
Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Erös, György Mészáros, Ferenc Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, György Kéri, László Orfi
ZUSAMMENFASSUNG

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Colchicin, ≥95% (HPLC), powder
Sigma-Aldrich
Theophyllin, anhydrous, ≥99%, powder
Sigma-Aldrich
Indol, ≥99%
Sigma-Aldrich
Valerophenon, 99%
Sigma-Aldrich
Colchicin, BioReagent, suitable for plant cell culture, ≥95% (HPLC)
Sigma-Aldrich
Benzimidazol, 98%
Sigma-Aldrich
Acetophenon, ReagentPlus®, 99%
Sigma-Aldrich
Acetophenon, ≥98%, FG
Sigma-Aldrich
Butyrophenon, ≥99%
Sigma-Aldrich
Indol, ≥99%, FG
Supelco
Acetophenon, analytical standard
Sigma-Aldrich
Acetophenon, puriss. p.a., ≥99.0% (GC)